Indian pharmaceutical companies are increasingly looking beyond domestic markets for growth opportunities through mergers and acquisitions (M&As). This trend is driven by challenges such as US tariff threats and price erosion in the generics market. In a significant move, Sun Pharmaceutical Industries, based in Mumbai, announced its acquisition of Organon, a US-listed women's healthcare company, for $11.75 billion. This acquisition aims to enhance long-term value and strengthen market positioning. Other notable deals include Zydus Lifesciences potentially acquiring a majority stake in Ardelyx Inc. for $2.5 billion, which would bolster its presence in the innovative medicine sector. Additionally, Intas Pharmaceuticals purchased the Udenyca franchise for $558.4 million, while Natco Pharma acquired a 35.75% stake in Adcock Ingram Holdings for $226 million. Lupin recently completed the acquisition of VISUfarma B.V. in the Netherlands for €190 million. These moves reflect a strategic shift among Indian drugmakers towards innovation and diversification in response to evolving market dynamics.